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Abstract
Introduction: Clinical guidelines recommend extended treatment with dual anti-
platelet therapy (DAPT) with ticagrelor 60 mg (twice daily) beyond 12 months in
high-risk patients with a history of myocardial infarction (MI) who have previously
tolerated DAPT and are not at heightened bleeding risk. However, evidence on pat-
terns of use and associated clinical outcomes in routine clinical practice is limited.
Methods: ALETHEIA is an observational, multi-country study, designed to
describe characteristics, treatment persistence, and bleeding and cardiovascular
(CV) outcomes in post-MI patients who initiate ticagrelor 60 mg in routine clinical
practice (NCT04568083). The study will include electronic health data in the
United States (US; Medicare, commercial claims) and Europe (Sweden, Italy,
United Kingdom, Germany). Characteristics will be described among patients with
and without ticagrelor 60 mg ≥1 year post-MI. Assuming an a priori threshold of
5000 person-years on-treatment is met, to ensure sufficient precision, clinical
outcomes (bleeding and CV events) among patients treated with ticagrelor
60 mg will be assessed. Risk factors for clinical outcomes and treatment discon-
tinuation will be assessed in patients with ticagrelor 60 mg and meta-analysis
used to combine estimates across databases. Cohort selection will initiate from
the ticagrelor 60 mg US and European approval dates and end February 2020.
An estimated total of 7250 patients prescribed ticagrelor 60 mg are expected to
be included.
Discussion: An increased understanding of patterns of ticagrelor 60 mg use and
associated clinical outcomes among high-risk patients with a prior MI is needed.
The a priori specified stepwise approach adapted in this observational study is
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1 | INTRODUCTION
Ischemic heart disease is the leading cause of death worldwide, with
myocardial infarction (MI) being the most common form.1 Despite
optimal secondary prevention therapies, the risk of experiencing
another major adverse cardiovascular (CV) event (MACE) in patients
who are event-free 1 year after MI is about 20% in the subsequent
3 years.2
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA)
and a P2Y12 inhibitor (e.g., ticagrelor, clopidogrel, prasugrel) reduces
the risk of CV events.3–5 Several studies have demonstrated a
reduced risk of CV events (e.g., stroke, MI, vascular death, stent
thrombosis) in patients treated with DAPT following an acute coro-
nary syndrome (ACS), but with an increased risk of major bleeding
when compared to ASA or a P2Y12 inhibitor alone.
4,6 In patients with
prior MI or coronary stenting, extended DAPT (i.e., for more than
12 months) is also associated with a significant reduction in the risk of
CV events, but a higher risk of major bleeding, compared to ASA
alone.4,5,7
The P2Y12 inhibitor ticagrelor, in combination with low-dose ASA,
is indicated for the prevention of CV events in patients with an ACS
or a history of MI. The PEGASUS-TIMI 54 trial demonstrated a lower
risk of MACE with extended DAPT with ticagrelor 60 mg (twice daily)
and ASA compared to ASA alone (HR 0.84; 95% CI 0.74, 0.95) in
patients with a history of MI.6 However, an increased risk of major
bleeding versus ASA alone was also observed (HR 2.32; 95% CI 1.68,
3.21). Similarly, the DAPT study demonstrated that extending DAPT
with either clopidogrel or prasugrel and ASA for up to 30 months fol-
lowing insertion of a drug-eluting stent for ACS or stable CAD
reduced the risk of MACE (HR 0.71; 95% CI 0.59–0.85) and stent
thrombosis (HR 0.29; 95% CI 0.17–0.48), compared to 12 months of
DAPT, albeit with an increased risk of moderate or severe bleeding
(2.5% vs. 1.6%, p = .001).5 Clinical guidelines recommend extending
DAPT, with ticagrelor 60 mg preferred over clopidogrel or prasugrel,
beyond 12 months in high-risk patients with a history of MI without
previous bleeding complications or conditions associated with high-
risk of major bleeding.8–10
It is well known that patients treated in routine clinical practice
may differ from those included in clinical trials, although there are lim-
ited observational data on patients initiating ticagrelor 60 mg post-
MI.11 Data from routine clinical practice are increasingly recognized as
a source of valuable information about patterns of medication use as
well as safety and effectiveness profiles of medications used in large,
heterogenous patient populations, as a complement to randomized
clinical trials.12 With growing attention on observational studies, the
use of high-quality electronic health data (EHD) from routine clinical
practice and the application of scientifically robust methodology is
crucial to ensure that the evidence generated is of sufficient quality to
inform decision-making, as also highlighted by the recent initiatives
from regulatory agencies in the United States (US) and Europe.13,14
This paper presents the rationale and design of ALETHEIA, an
observational study with the primary objective to describe patient
characteristics, treatment persistence, and event rates of bleeding
requiring hospitalization in a large multi-country cohort of patients
treated with ticagrelor 60 mg after an MI. Additional objectives
include to describe event rates for a CV composite outcome (hospital-
ization for MI or stroke, and all-cause mortality), and to describe treat-
ment persistence and event rates in patient subgroups. In addition,
baseline risk factors associated with bleeding and CV events, as well
as with treatment discontinuation, will be explored. To contextualize
the characteristics of patients initiating ticagrelor 60 mg, characteris-
tics will also be described for patients treated with a P2Y12 inhibitor
other than ticagrelor (clopidogrel, prasugrel, or ticlopidine), as well as
patients not treated with any P2Y12 inhibitor at a similar point in time
from their MI as observed among patients initiating ticagrelor 60 mg.
2 | METHODS
2.1 | Study design
ALETHEIA is an observational, multi-country study using retrospec-
tive EHD extracted from multiple sources in the US and in several
European countries (Germany, Italy, Sweden, and the United Kingdom
[UK]). The full list of objectives is presented in Table 1. The study is
registered at www.clinicaltrials.gov (NCT04568083).
To maximize patient inclusion and ensure a sufficient look-back
period to appropriately identify eligible patients, the study will span a
broad eligibility period from the earliest date of data availability to the
most recent data available at data extraction from each database. In
general, the eligibility period will begin at least 3 years prior to the
ticagrelor 60 mg approval date (European Union [EU]: 19 December
2015; US: 3 September 2015).
2.2 | Patient populations
To account for differences between clinical trial selection criteria and
geographic adaptations of labels for ticagrelor 60 mg, the study
includes both a Primary and a Secondary population. The Primary
2 LESEN ET AL.
population is defined to align as close as possible with the
PEGASUS-TIMI 54 eligible population and the US approved label.6
The Secondary population is defined to align as close as possible to
the European approved label.15–18 Both study populations will be
defined in each data source. For all databases, cohort selection will
begin on the US ticagrelor 60 mg approval date for the Primary pop-
ulation and on the EU approval date for the Secondary population.
Across databases, the latest date of the cohort selection period will
be 29 February, 2020.
The full eligibility criteria are described in Table 2. Briefly, the
Primary population will include patients with a first prescription of
ticagrelor 60 mg ≥12 months after their most recent hospitalization
with a primary diagnosis of MI (i.e., their qualifying MI). The Second-
ary population will include patients with a first prescription of
ticagrelor 60 mg, either (i) 12–24 months following their qualifying
MI, or (ii) 12–36 months following their qualifying MI and with
P2Y12 inhibitor treatment ≤12 months prior to the first ticagrelor
60 mg prescription. The date of the first ticagrelor 60 mg prescrip-
tion following the qualifying MI will be defined as the index date.
The exclusion criteria are based on PEGASUS-TIMI 54 and include a
history of ischemic stroke, intracranial bleeding, hepatic impairment,
gastrointestinal bleeding, stage 5 chronic kidney disease (CKD), or
renal failure. In recognition that the timing of ticagrelor 60 mg initia-
tion may vary in clinical practice, the study will also include the
Anytime cohort, a complementary population comprising patients
with a first prescription of ticagrelor 60 mg any time after their
qualifying MI.
To contextualize the characteristics of patients initiating
ticagrelor 60 mg, two reference cohorts will be defined, the non-
ticagrelor P2Y12 inhibitor cohort and the non-P2Y12 inhibitor cohort,
applying otherwise similar eligibility criteria as for the Primary and
Secondary populations. To assign reference patients into these
cohorts, the median distribution of time from qualifying MI to index
date in the Primary population will first be described. The rationale is
to ensure that characteristics of reference patients are described at a
similar time from their qualifying MI as for patients initiating ticagrelor
60 mg. Based on this median time, a treatment exposure window will
be defined to categorize patients into the respective reference
cohorts based on their treatment within this window. The non-
ticagrelor P2Y12 inhibitor cohort will include patients treated with
clopidogrel, prasugrel, or ticlopidine at the end of the treatment win-
dow. The non-P2Y12 inhibitor cohort will include patients without
TABLE 1 Study objectives
Objectives
Primary 1. To describe the demographic, clinical, and treatment characteristics of patients initiating ticagrelor 60 mg treatment, at the time of
their qualifying MI and at the time of treatment initiation (index date).
2. To describe the persistence and, where feasible, adherence, to treatment with ticagrelor 60 mg, including treatment discontinuation
and treatment switch.
3. To describe the cumulative incidence and event rates (incidence rate and all-event rate) of bleeding requiring hospitalization in
patients treated with ticagrelor 60 mg using an on-treatment approach.a
Secondary 1. To describe the cumulative incidence and event rates (incidence and all-event rates) of the composite of MI, stroke, and all-cause
mortality in patients treated with ticagrelor 60 mg using an on-treatment approach.a
2. To describe treatment persistence, event rates of bleeding requiring hospitalization, event rates of the composite of MI, stroke, and
all-cause mortality, and event rates of their respective individual components using an on-treatment approach, in patient
subgroups.a
3. To describe the type and pattern of discontinuation and re-initiation of antiplatelet drugs used in the subgroup of patients who
undergo an elective PCI after the index date.
Exploratory 1. To analyze the associations between specific patient characteristics assessed at index date and the risk of bleeding requiring
hospitalization, and of the composite endpoint of MI, stroke, and all-cause mortality, and of their respective individual components,
for patients treated with ticagrelor 60 mg using an on-treatment approach.a
2. To describe patient characteristics at the time of MI and at the assigned index date among patients in a non-ticagrelor cohort who
are treated with a P2Y12 inhibitor other than ticagrelor (clopidogrel, prasugrel, or ticlopidine).
3. To describe patient characteristics at the time of MI and at the assigned index date among patients in a non-ticagrelor cohort who
are not treated with any P2Y12 inhibitor.
4. To describe event rates of bleeding outcomes (intracranial bleeding, gastrointestinal bleeding, and other bleeding requiring
hospitalization, fatal bleeding, bleeding not requiring hospitalization), of CV outcomes (recurrent MI, all-cause stroke, ischemic
stroke, CV death, CHD death), all-cause mortality, and of dyspnea and lower limb amputation in patients treated with ticagrelor
60 mg using an on-treatment approach.a
5. To conduct sensitivity analyses (for the primary bleeding outcome and the secondary CV composite outcome) for primary objective
3, secondary objectives 1 and 2, and exploratory objective 1 using an intention-to-treat approach instead of an on-treatment
approach. a
6. To investigate the associations between patient characteristics (measured at the index date) and the risk of discontinuing
ticagrelor 60 mg.
Abbreviations: CHD, coronary heart disease; CV, cardiovascular; MI, myocardial infarction; PCI, percutaneous coronary intervention.
aThe total number of person-years on treatment in the Primary population will be assessed across all countries. Clinical outcomes in this study will not be
analyzed unless the a priori threshold of 5000 person-years on-treatment with ticagrelor 60 mg is met in the Primary population, as a total across all data
sources.
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P2Y12 inhibitor treatment at the end of this window. A schematic
illustration of all cohorts is presented in Figure 1.
2.3 | Data sources
To obtain a large and geographically diverse population, data will be
extracted from data sources in the US and several European countries
(Germany, Italy, Sweden, and the UK). Table 3 presents detailed infor-
mation on each database, along with projected numbers of patients ini-
tiating ticagrelor 60 mg ≥1 year after their most recent MI available at
the time of data extraction. In general, the study will use data on inpa-
tient and outpatient care, prescriptions, and mortality when available.
An estimated total of 7250 patients prescribed ticagrelor 60 mg are
expected to be included across databases.
2.4 | Definition of treatment exposure and
persistence
Treatment persistence for ticagrelor 60 mg will be defined as time on
continuous treatment. To account for potential stockpiling, overlapping
prescriptions will be assumed to be used sequentially. The treatment
episode will be considered as continuous if the gap between days with
available medication supply (grace period) is less than two times the
number of days' supply of the most recent prescription. Patients with no
further evidence of treatment before the end of the grace period will be
defined as having discontinued treatment. The discontinuation date is
defined as the date of the last prescription plus the number of days'
supply in that last prescription plus 7 days, or the date of switch, or the
date of death, whichever occurs first.
2.5 | Clinical outcomes
Study measures, including outcomes, are defined using diagnosis, pro-
cedure, and medication codes in the formats used in each database;
full definitions are presented in Table S1.
To ensure sufficient precision, clinical outcomes for all study
populations will only be analyzed if the a priori threshold of 5000
person-years on-treatment with ticagrelor 60 mg is met in the Primary
population, as a total across all data sources.
The primary outcome, bleeding requiring hospitalization, is
defined as an inpatient admission with at least one overnight stay
TABLE 2 Study inclusion and exclusion criteria
Primary population Secondary population
Inclusion criteria
• Hospitalization with a primary diagnosis of MI
during the eligibility period
• Hospitalization with a primary diagnosis of MI during the eligibility
period
– • Age ≥ 50 years at the index date
– • At least one of the following risk factors assessed at the index date:
– • Age ≥ 65 years
• Diabetes mellitus requiring medication (defined as ≥1 prescription
any time prior to the index date)
• A second prior MI (defined as hospitalization with a primary
diagnosis of MI in the baseline period with the date of diagnosis
>30 days prior to the date of qualifying MI)
• Chronic non-end-stage renal dysfunction (defined as a diagnosis of
CKD stage 1 to 4 in the baseline period)
• A first prescription of ticagrelor 60 mg ≥12 months
following their qualifying MI
• A first prescription of ticagrelor 60 mg and one of the following
criteria:1) 12–24 months after their qualifying MI, or 2)
24–36 months after their qualifying MI and treatment with an
P2Y12 inhibitor ≤12 months prior to the first ticagrelor 60 mg
prescription
Exclusion criteria
• Dies, emigrates, or disenrolls from the database (where applicable) prior to the ticagrelor 60 mg approval date
• Ineligibility for ticagrelor 60 mg use (restricted to the conditions possible to capture within the data sources)—one or more of
the following:
• Concomitant use of an anticoagulant or a strong CYP3A4 inhibitor or inducer or substrate with a narrow therapeutic index
(prescription within 60/90 days prior to the index date)
Prior ischemic stroke, history of intracranial bleeding, severe hepatic impairment, CKD stage 5 or renal failure requiring dialysis
(any time prior to the index date)
• Gastrointestinal bleeding (within 6 months prior to the index date)
• <1 year of data available prior to the qualifying MI (for assessment of patient characteristics at qualifying MIa)
Abbreviations: CKD, chronic kidney disease; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction.
aThe qualifying MI is defined as the most recent hospitalization with a primary diagnosis of MI occurring prior to initiation of ticagrelor 60 mg (index date).
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with a primary diagnosis of bleeding. In a sensitivity analysis, the pri-
mary bleeding outcome is defined as bleeding events associated with
an inpatient admission of ≥2 overnight stays. Additional bleeding out-
comes include the individual components of the primary outcome
(hospitalization for intracranial hemorrhage, gastrointestinal bleeding
and other bleeding, respectively), bleeding episodes not requiring hos-
pitalization, and fatal bleeding.
Outcomes were identified on the event date recorded in the
EHD; for composite outcomes, the earliest date of any of
the components was used to define the event date. The second-
ary CV composite outcome is defined as the composite of hospi-
talization for MI or stroke, and all-cause mortality. Additional
outcomes include the individual components of the secondary CV
composite outcome, three-point MACE (composite of hospitaliza-
tion for MI or stroke, and CV death), hospitalization for ischemic
stroke, CV death, as well as coronary heart disease (CHD) death.
To ensure harmonized definitions across all databases, fatal bleed-
ing, CHD death, and CV disease (CVD) death are defined as
death within 28 days of an inpatient hospital admission with a pri-
mary diagnosis of bleeding, CHD, and CVD, respectively. Sensitiv-
ity analyses for these outcomes will be performed in databases
reporting cause of death from death certificates (UK and Sweden).
Exploratory outcomes include dyspnea and lower-limb amputation,
as well as bleeding requiring transfusion (only available in the US
databases).
Due to insufficiently detailed clinical data in all databases to
adequately adjust for imbalances in clinical characteristics between
cohorts for comparative analyses, clinical outcomes will only be
analyzed in the ticagrelor 60 mg cohorts (i.e., not in the reference
cohorts).
Subgroup analyses of interest are described in Figure 2.
2.6 | Study organizational structure
The study will be conducted by the sponsor (AstraZeneca) in collabo-
ration with a contract research organization (Evidera), encompassing
both cardiology and epidemiology expertise, with oversight from a sci-
entific committee of cardiology experts external to both companies.
The external scientific committee is responsible for: (i) The planning,
development and scientific integrity of all publications and presenta-
tions derived from the ALETHEIA study in collaboration with
AstraZeneca; (ii) The content and implementation of the study proto-
col and analysis plan, its interpretation, and reporting of the study
results. All authors take responsibility for the veracity of the data. Full
details of the study organization are provided in Table S2.
2.7 | Statistical analyses
Patient characteristics (as outlined in Figure 2) will be summarized
at qualifying MI and at index date for patients treated with
ticagrelor 60 mg, for the nonticagrelor P2Y12 inhibitor cohort, and
for the non-P2Y12 inhibitor cohort using descriptive statistics. All
other statistical analyses will be performed among patients treated
with ticagrelor 60 mg.
F IGURE 1 Schematic illustration of cohorts ASA, acetylsalicylic acid; MI, myocardial infarction. a Treated with a P2Y12 inhibitor (clopidogrel,
prasugrel, ticagrelor 90 mg, or ticlopidine) ≤12 months prior to the ticagrelor 60 mg prescription. b ASA analyses will only be done when data available
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patients at time of
data extractiona
US Optum Clinformatics® administrative claims database
combines data from over 50 healthcare providers in
the US (>700 hospitals and 7000 clinics). The
database provides a single-payer view of data on
demographics, diagnoses, and procedures performed
during outpatient visits (outpatient specialist and
physician visits) or inpatient stays, and outpatient
prescription records (i.e., date of dispensed
prescriptions). As is typical for US commercial claims
databases, comprehensive data on mortality is not
available in the Optum Clinformatics database.
180 million; 55% 750
IBM's MarketScan Commercial Claims and Medicare
Supplemental database consists of administrative
claims submitted from US inpatient and outpatient
encounters, as well as pharmacy claims (i.e., date of
dispensed prescriptions). Medical claims are linked to
outpatient prescription drug claims and person-level
enrollment information. The MarketScan
supplemental database profiles the healthcare
experience of retirees with Medicare supplemental
insurance paid by employers. The Medicare
Supplemental database provides data on medical and
pharmacy claims for healthcare services performed
in both inpatient and outpatient settings (i.e., date of
dispensed prescriptions). As is typical for US
commercial claims databases, comprehensive data
on mortality is not available in the MarketScan
database.
203 million; 62% 1200
Medicare health insurance database covers fee-for-
service claims data of individuals who are aged
≥65 years, select individuals with disabilities aged
<65 years, and those with end-stage renal disease.
The data cover beneficiaries' encounters with the
healthcare system and receipt of therapeutic
interventions, including medications (i.e., date of
dispensed prescriptions), procedures, and services.
Data on mortality are available.
62 million; 19% 3100
UK CPRD GOLD contains longitudinal primary care data
from over 800 general practices, whereas CRPD
Aurum holds anonymized, longitudinal, primary care
patient records collected from over 1100 general
practices. Data includes information on patient
characteristics and issued prescription medicines.
HES covers data on diagnoses and procedures for all
hospitalization episodes from England, whereas ONS
covers information on all-cause and cause-specific
death. Data from both HES and ONS will be linked
to primary care data of the CPRD. After removal of
duplicates, GOLD and Aurum primary care databases
will be used for the analysis.
13.5 million; 24% (GOLD
+Aurum)
250
Sweden The National Patient Register includes information on
hospital discharge diagnoses and procedures. The
Swedish Prescribed Drug Register covers data on all
prescribed medications purchased at Swedish
community pharmacies. The Cause of Death
Register includes information on date and cause of
death. The registers are linked by the register holder
via the unique personal identification number.
10 million; >99% 800
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Persistence to treatment with ticagrelor 60 mg, including median
time until discontinuation (if and when reached during follow-up), and
the percentage of patients remaining on treatment at specific
timepoints from index date (Figure 2), will be calculated using the
Kaplan–Meier (KM) method. Additionally, switches to another P2Y12
inhibitor or an anticoagulant will be similarly calculated.
The KM method will be used for calculating median times to clini-
cal outcome events (if and when reached during follow-up) and cumu-
lative incidence at specific time points (Figure 2), presented along
with 95% confidence intervals (CI). Incidence rates per 100 person-
years along with 95% CI will be calculated as the total number of
patients with the event during follow-up divided by the total person-
time at risk; during the intervals outlined in Figure 2. For events that
can occur more than once, the all-event rates (i.e., wherein patients
are not censored at the occurrence of the event of interest) will also
be calculated within the same intervals. Diagnoses for the same type
of event recorded within 30 days will be assumed to be for follow-up
care, rather than a new event. For all outcomes, only timepoints at
which a minimum of five events are recorded will be described.
Cox proportional hazards regression models will be used to assess
the association of baseline patient characteristics (measured at index
date) with the risk of the primary bleeding outcome, with the second-
ary CV composite outcome and with treatment discontinuation,
respectively. Hazard ratios (HR) and 95% CIs will be presented.
The primary outcomes analyses will be based on an on-treatment
approach, censoring at treatment discontinuation. Additionally, an
intention-to-treat approach will be used as a sensitivity analysis for
the primary bleeding outcome and the secondary CV composite out-
come. Sensitivity analyses will also be performed using two alternative
definitions of treatment discontinuation, where the grace period is
defined as 60 days in all databases, or where the discontinuation date
is defined as the date of the last prescription of ticagrelor 60 mg plus
half the number of days' supply in that last prescription plus 7 days.
Meta-analyses will be applied to combine estimates derived from
each country/database. Each meta-analysis will be preceded by an
assessment of heterogeneity in terms of patient characteristics and
estimates. Heterogeneity will be quantified by the I2-statistic,19
and reasons for any observed heterogeneity will be explored prior to
estimating the components of the meta-analysis. A fixed-effects
approach will be used as the main method; random-effects analyses
will also be performed. The meta-analysis results will be presented in
Forest plots displaying the individual database-level estimates with
corresponding 95% CIs.
Regression models combined in the meta-analyses will use
predefined sets of covariates. These covariates will be selected based
on the results of the country-level regression models and clinical
knowledge.
2.8 | Sample size estimation
No power calculations were performed as all objectives are descrip-
tive in nature. The a priori threshold of 5000 person-years on-
treatment for outcomes analyses among patients treated with
ticagrelor 60 mg was based on an assumed event rate for bleeding
requiring hospitalization of 0.5 per 100 person-years (the annualized
major bleeding rate was approximately 0.9% in the PEGASUS-TIMI
54 trial).17 With a sample size of 5000 patients (assuming an average
of 1 year on treatment), the 95% CI would be 0.3–0.7 events per







patients at time of
data extractiona
Germany AOK PLUS covers longitudinal claims data submitted
from primary, secondary, and tertiary care, and
contains information on patient demographics,
inpatient hospitalizations, outpatient visits,
procedures, mortality (inpatient and outpatient date
of death), and outpatient prescriptions dispensed in
pharmacies.
3.5 million; 4% 150
Italy ReS database includes data on patient demographics,
pharmacy-dispensed prescription drugs, inpatient
diagnoses and procedures, and date of in-hospital
mortality. For deaths in the outpatient setting,
neither date of death nor cause of death is recorded
in ReS.
5.5 million; 10% 1000
Total estimated number of patients included across databasesa 7250
Abbreviations: AOK, Allgemeine Ortskrankenkasse; CPRD, Clinical Practice Research Datalink; HES, hospital episode statistics; IBM, International Business
Machines; MI, myocardial infarction; ONS, Office for National Statistics; ReS, Ricerca e Salute; Italian Research and Health Foundation; UK, United
Kingdom; US, United States.
aProjected approximate numbers of patients initiating ticagrelor 60 mg ≥1 year after their most recent MI, expected to be available in the data sources at
the time of data extraction.
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stroke, or CV death) was expected to be approximately 2.5 per
100 person-years (the annualized rate for this outcome was approxi-
mately 2.7% in the PEGASUS-TIMI 54 trial).17,20 Given that this out-
come is expected to occur more frequently than bleeding requiring
hospitalization, the threshold of 5000 person-years will be applied for
all clinical outcome analyses.
2.9 | Ethical considerations
This observational study will be performed in accordance with ethical
principles consistent with the Declaration of Helsinki and the Interna-
tional Society for Pharmacoepidemiology guidelines on Good Phar-
macoepidemiology Practice. The final protocol has been approved by
Ethics Committees/Institutional Review Boards, as applicable in each
of the countries.
This study does not involve any primary data collection; hence,
subject informed consent is not applicable.
3 | DISCUSSION
ALETHEIA aims to enhance the understanding of patient character-
istics, treatment patterns, and bleeding and CV outcomes in
patients with a history of MI on extended DAPT with ticagrelor
60 mg in routine clinical practice. The study will include patient-
level data from seven observational EHD sources from five coun-
tries across Europe and the US, to obtain a large and geographically
diverse patient sample. The main study populations are defined to
align, as much as possible in observational EHD, with the overall
PEGASUS-TIMI 54 population (the Primary population)6 and its
subgroup relevant to geographic adaptations of the ticagrelor
60 mg label (the Secondary population, aligned with the European
label).17,18 Given the lack of robust data on ticagrelor 60 mg use in
routine clinical practice, ALETHEIA is therefore designed to supple-
ment and further explore clinical trial findings by generating infor-
mation that may be used to guide appropriate patient selection for
this therapy.
F IGURE 2 Study design ASA, acetylsalicylic acid; CKD, chronic kidney disease; CV, cardiovascular; MI, myocardial infarction; PAD, peripheral
artery disease; PCI, percutaneous coronary intervention
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The stepwise design with an a priori threshold of person-years on
treatment has been implemented to ensure that precise estimates of
clinical outcomes can be calculated, to more accurately inform clinical
decision-making.
Data from routine clinical practice on prescription patterns and
clinical outcomes in patients treated with ticagrelor 60 mg post-MI
are very limited. In a recent observational study in 181 patients in
Italy, including those with a previous MI treated with ticagrelor 60 mg
twice daily plus aspirin, the 1-year risk of MACE was 5.0%, with MI
being the main contributor (3.9%), while no major bleeding events
occurred.11
Based on the TWILIGHT trial21 findings and latest updates to clin-
ical guidelines,8 monotherapy with a P2Y12 inhibitor is an emerging
treatment strategy for patients post-percutaneous coronary interven-
tion. In this study, all patients are assumed to be on concomitant ASA,
since data on medications that can be purchased without a prescrip-
tion, such as ASA, are not available in all countries. Based on the prod-
uct labels and the time period in which the observations the
ALETHEIA study took place (most patients pre-2019), concomitant
use of ASA is a reasonable assumption. The extent of
concomitant ASA use will be described in databases capturing this
data, to assess consistency with this assumption.
One strength of this study is that patient characteristics will also
be described among patients treated with a nonticagrelor P2Y12 inhib-
itor and those who are not treated with any P2Y12 inhibitor, at a com-
parable time from their MI to patients initiating ticagrelor 60 mg. This
will provide useful contextualization of the findings, as patient charac-
teristics (e.g., risk factors, disease severity, comedications), prescriber
preferences, and local guidelines may influence the selection of treat-
ments prescribed in clinical practice. The main reasons for not per-
forming comparative outcomes analyses include the expected lack of
complete information on all covariates assumed to be needed to ade-
quately balance the populations for baseline risk, leading to potential
residual confounding, as well as key methodological challenges for
comparative analyses, such as determining use of low-dose ASA,
which is not captured in all databases. While the data are physician-
reported and the claims data are adjudicated for reimbursement pur-
poses, no additional adjudication of clinical events is performed, a limi-
tation shared with most observational database studies. However,
some databases used in the study (e.g., the Swedish National Inpatient
Register) have been validated for clinical diagnoses, including CV
disease.22,23
The study also has a number of limitations typical of multi-coun-
try, register-based, observational studies. First, while the data sources
used in this study reflect routine clinical practice, they are not primar-
ily established for research purposes. Therefore, coding practices of
diagnoses and medications (e.g., prescriptions issued vs. filled) may
vary between databases. While study definitions have been harmo-
nized across databases and based on validated algorithms wherever
possible,22 these differences may influence the ascertainment of
patients for inclusion in the study and of clinical outcomes. Second,
characteristics and baseline risks may differ between countries due to
differences in patient characteristics, healthcare systems, prescribing
practices, and other population-level factors. This may limit our ability
to conduct meta-analyses, as well as the generalizability of the study
findings, but this limitation is offset by the advantages of using multi-
ple databases, which includes increased geographical representative-
ness and sample size. In this study, analyses are harmonized using
common definitions across the databases. Additionally, sensitivity
analyses (e.g., around prescription length) and the calculation of the
I2-statistic for meta-analyses intends to mitigate and quantify hetero-
geneity across databases. While outcomes based on cause of death
will be defined using the same definition across all databases to
ensure harmonization, the contextualization of these findings with
sensitivity analyses using data from death certificates (available from
UK and Sweden) will be a valuable contribution in advancing method-
ology in observational studies. Third, the European databases included
in this study do not contain comprehensive information on blood
transfusions, so major bleeding events are primarily defined using only
inpatient diagnostic codes for bleeding. Still, an exploratory outcome
on bleeding requiring transfusions will be assessed in the US data-
bases, where transfusion procedures are expected to be more reliably
captured. Furthermore, common bleeding definitions used in random-
ized trials require laboratory parameters to categorize bleeding
events, but as this information is not consistently available from EHD
sources, bleeding scales were not used in in ALETHEIA. Since compre-
hensive information on mortality is available in US Medicare claims
but not in Optum Clinformatics and IBM MarketScan, additional
meta-analyses of outcomes, whether or not these outcomes include
death, will be performed as a sensitivity analysis in a restricted study
population, excluding patients from the Optum and MarketScan data-
bases. The rationale is to provide results for both the bleeding and CV
outcomes in populations with similar age distributions.
Fourth, the 5000 person-years on treatment threshold is consid-
ered as the minimum number required for sufficient precision in clini-
cal outcome assessment. While this threshold is expected to be met,
person-years on treatment is a function of both time on treatment
and number of patients, and is thereby influenced by the databases'
available duration of longitudinal data as well as their national
coverage.
Fifth, to allow contextualization of patient characteristics, refer-
ence cohorts of nonticagrelor patients will be described at a similar
time point from their qualifying MI as will be observed among the
patients initiating ticagrelor 60 mg. In routine clinical practice, patients
treated for ACS may continue being prescribed a P2Y12 inhibitor more
than 12 months after an MI, despite not being intended for extended
antiplatelet treatment. To limit the inclusion of such patients in the
nonticagrelor P2Y12 inhibitor cohort, categorization of patients into
either reference cohort will be based on their treatment at a minimum
of 15 months after their qualifying MI. Exposure to nonticagrelor
P2Y12 inhibitors or lack of exposure to P2Y12 inhibitors may therefore
be assessed after the index date for some patients, introducing a sur-
vival bias to patients in the reference cohort. Although the extent of
this bias cannot be quantified a priori, the impact is likely minimal
given the short maximum timeframe between the index date
(≥12 months post-MI) and the time of treatment assessment
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(≥15 months post-MI). Sixth, while the primary analyses will be con-
ducted using an on-treatment approach, reflecting events that occur
when patients are receiving ticagrelor 60 mg, censoring at treatment
discontinuation may introduce bias due to informative censoring. This
could occur if the risk of discontinuing treatment is related to the
events of interest, thus violating the key assumption in survival ana-
lyses that censoring events are random. While difficult to properly
account for, the likelihood of such bias being introduced will be
assessed by investigating baseline factors associated with discontinu-
ation. To further assess the potential risk of informative bias, event
rates will also be calculated using an intention-to-treat approach.
In conclusion, despite the increasing recognition of observational
studies to inform healthcare decision-making, knowledge about treat-
ment patterns and associated outcomes in patients treated with
ticagrelor 60 mg in routine clinical practice is limited. The multi-coun-
try, observational ALETHEIA study is designed to address this gap.
The study objectives and the a priori specified stepwise approach
used for outcomes analyses are expected to generate useful insights
for clinical decision-making and treatment optimization.
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